Solvay Pharmaceuticals acquires Innogenetics
Solvay Group holds 84.3% of Innogenetics shares
11-Sep-2008 -
Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer on Innogenetics shares ran from 12 August to 5 ...
biomarker
diagnostics
Solvay